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TRENDS AND PREDICTORS OF WOMEN’S RISK PERCEPTION ABOUT 
MEDICATIONS THAT MAY CAUSE BIRTH DEFECTS 
MARK JOSEPH SAMUELSON 
ABSTRACT 
 The purpose of this study was to evaluate the proportion of women who reported 
perception of medications as a risk for birth defects, whether perceptions have changed 
over time, and identify socioeconomic and medical factors that are independent 
predictors of perception of medication risk. The information gained may be useful in 
developing strategies for the risk management of known teratogens and enhancing the 
appropriate use of medications known to be safe. 
 From 1976 to 2015, 51,413 women from the Slone Epidemiology Center Birth 
Defect Study (Slone BDS) were interviewed about whether they were aware of any 
medication or other substance that might cause birth defects, and about sociodemographic 
and medical factors. This analysis focused on those participants who reported one or 
more medication (or vitamin) as a risk factor for birth defects.   
 The results demonstrated a general trend towards fewer women perceiving 
medication risk over the past four decades. The proportions of women who reported 
perception were higher for the following variables:  older maternal age, white race, 
higher educational levels, previous pregnancy of a child with reported birth defects, daily 
medication use during pregnancy, wanted pregnancy, and alcohol use during pregnancy. 
The study does not support the likelihood of recall bias in women who gave birth to a 
		 vi 
baby with a birth defect, an important concern in epidemiological studies of birth defects.  
  Misconception of risk was identified; of the top ten medications reported as 
potentially teratogenic, only three (thalidomide, isotretinoin, and diethylstilbestrol) are 
established teratogens. Overestimation of risk could potentially impact a woman’s 
decision to continue a pregnancy or cause unnecessary anxiety when using a medication 
that is needed during pregnancy. It has previously been shown that counseling pregnant 
woman can decrease the misperception of teratogenic risk from medications used for 
nausea and vomiting of pregnancy. Other researchers have suggested that greater use of 
drug information centers, such as the Norwegian network of drug information centers 
(RELIS), may help guide pregnant women and prescribing providers to improve 
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The general public may have learned that medications can cause birth defects 
when used during pregnancy after the thalidomide disaster in the late 1950s and early 
1960’s.1  Since that time there has been heightened focus on risk evaluation of the 
teratogenic risks of medications and communication of potential risks to the public.2 
Common sources of information about the risks of medications taken during pregnancy 
include health professionals who take care of women, the medical literature, and the lay 
media. 3, 4, 5    There is limited information about women’s perception of medication risk 
during pregnancy, whether perceptions have changed over time, and if perception is 
related to socio-economic or other factors.  
The process of risk assessment in pregnancy is considered multidimensional, 
involving self-image, personal and family health history, confidence in health care 
services, and fear of the unknown.6  Investigators have demonstrated that variations in the 
presentation (framing) of risk information can affect women's perception of fetal risk and 
the subsequent use of medications during pregnancy.7 Early studies suggested that the 
majority of women recognized the risk of tobacco, alcohol, and medication consumption 
during pregnancy..8  However, it has been shown that professionals and the public may 
perceive a medication to have a higher degree of risk than has been identified in formal 
studies.9, 10 Overestimation of risk could potentially impact a woman’s decision to 
continue a pregnancy or cause unnecessary anxiety when using a medication that is 
needed during pregnancy.   
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It has been shown that perception of risk from medications can vary according to 
age and education level; higher rates of perception of known teratogens were generally  
associated with increased age and higher educational level, however, associations with 
age and education were in the opposite direction when  perception of risk to over the 
counter and prescription medications was tested. 11     
Scientific publications concerning the relationship between medications and birth 
defects have increased over time. For example, a search of the number of publications 
listed in current PubMed containing the key words “birth defects” and “drugs” reveals an 
increase from 411 in 1976 through 1980 to 1820 in 2011 through 2015. The frequency of 
U.S. newspapers containing  the same key words increased from 212 to 950 during the 
same time periods (LexisNexis, 2018). One might predict that increasing information 
available over time in both scientific and public arenas would translate to a temporal 
increase in women’s perceptions of medication-related causes of birth defects.  
Further analysis of variables that are potentially related to risk perception may 
provide information useful for developing strategies for the risk management of known 
teratogens and enhancing the appropriate use of medications known to be safe. 
 
Objectives 
 The objectives of this study are to evaluate (1) women's perception of medications 
as a cause of birth defects, (2) whether perceptions have changed over time, and (3) if 




 The proportion of women who reported their perception that medications might 
cause birth defects has increased over the past 4 decades. Maternal education, pregnancy 
wantedness, and whether a woman had a previous pregnancy affected with a birth defect 
are associated with increased perception of medication risk.  Perception of risk is  higher 
in women who had a baby with a birth defect, offering indirect evidence of recall bias. 
 
Study Population 
 Data were obtained from the Slone Epidemiology Center Birth Defect Study 
(Slone BDS), a case-control surveillance program conducted since 1976, in which 
children with birth defects are ascertained at birth and tertiary care hospitals in greater 
metro Boston, Philadelphia, Toronto, Iowa, San Diego, New York, and Nashville. Since 
1993, a sample of mothers with unaffected  infants in these regions was also included, 
and since 1998, a population-based sample of mothers of infants who were unaffected 
had been recruited from Massachusetts. Within 6 months of delivery, trained study nurses 
interviewed mothers. Interviews were conducted face-to face (primarily in the woman’s 
home) before 1998 and by telephone after that time. The interview included questions on 
demographic characteristics and a detailed history of the use of medications, alcohol 
intake, and smoking from 2 months before conception throughout the entire pregnancy. 
In addition, at the end of the interview, each woman was asked to describe any factor that 
she thought might cause birth defects. Institutional review board approval was obtained 
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from relevant institutions, and mothers provided informed consent before participation.12 
The Slone BDS contains information from 1976 to 2015 on more than 51,000 mothers, 
including  38,285 who had a child with a birth defect and 13,128 with unaffected infants. 
 
Measurements 
Dependent Variable  
Perceived Risk - Perceived medication risk is defined as a positive response to the 
question: “Have you heard of any medications, vitamins or anything else that may cause 
birth defects?” * and the report of one or more medication (or vitamin) when asked the 
question “Can you name any medication or substance in particular?” Participants who 
meet both of these requirements will be considered to have perceived risk and they will  
be compared to those who answered no to the perception question. 
*Exact wording of this question has changed over time periods (Appendix A) 
 
Independent Variables  
Covariates selected were common maternal and  socio-economic factors including age 
and education, both previously shown to be associated with risk perception.  Markers for 
risk taking behavior during pregnancy including  alcohol use, smoking, and medication 
use, and factors potentially predictive of an increased  perceived risk including pregnancy 
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wantedness and  history of a previous child with a birth defect were selected as 
covariates. 
Interview year – Interviews were conducted from 1976 through 2015. Interview years 
were categorized in two ways; 1) 1976–1980, 1981–1985, 1986-1990, 1991-1995, 1996-
2000, 2001-2005, 2006-2010, 2011–2015 and 2) 1998-2000, 2001-2005, 2006-2010, 
2011–2015.  
Study centers - Massachusetts, Philadelphia, Toronto, Iowa, San Diego, New York, 
Nashville. 
Maternal age at time of interview (years)  < 21,  21-25, 26-30, 31-35, 36-40, > 40. 
Race/ethnicity - While, Black, Hispanic/Latino, Asian/Pacific Islander, Native 
American/Alaskan/Canadian, Other/Mixed race. 
Educational level of mother (years)  < 12, 12-15, > 15. 
Parity – Primiparous, Multiparous. 
Pregnancy wantedness- Wanted then, Wanted later, Did not want, Did not care (1998-
2015). 
Married - Yes, No (1998-2015). 
Index pregnancy affected with a birth defect - Yes, No. 




Alcohol use- Never or before pregnancy only, Drank during pregnancy (1998-2015). 
Previous pregnancy affected with a birth defect – Yes, No. 
 
Daily use of one or more medications (excluding vitamins)  during pregnancy (varying 
durations) – Yes, No.  
 
Statistical Analysis 
  Frequency distributions were calculated for each independent variable.  We 
calculated the percent of women reporting perception of medication risk of one or more 
medication (or vitamin) using the total number of women in each independent variable 
category as the denominator.  Logistic regression models were used to calculate 
univariate and multivariable odd ratios (ORs) and 95% confidence intervals (CIs).  
Categories of independent variables compared to a reference group were evaluated 
independently in relation to perception. ORs for variables with associations (confidence 
intervals did not include one in the univariate analysis) were evaluated to see if they 
remain as independent predictors in the multivariable analysis. Participants with missing 
variable data were excluded from univariate and multivariable models.  
 Two models were used for the analysis. Model 1 contains the entire population 
from 1976 through 2015. Model 2 contains only participants interviewed between 1998 
through 2015. Model 2 allows for the inclusion of three additional variables: pregnancy 
wantedness, marital status, and alcohol use. 
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 Potential multicollinearity of all variables was evaluated by calculating the 
Variance Inflation Factor (VIF) using the model 2 subset. Data were analyzed using SAS 
9.4 software.  
 Two analyses using the same procedures noted above were performed post hoc to 
test for differences in overall associations and trends. The first analysis included  3,251 
additional participants that were excluded from the original analysis because they 
answered yes to the perception question but did not report a medication (or vitamin).  The 
second analysis restricted the definition of perceived risk to only those who perceived 
one or more of the known teratogens thalidomide, isotretinoin, or diethylstilbestrol, 
compared to those who did not perceive, those who perceived other medications, and 
those who perceived only non-medication substances. 
 Frequency  distributions of medications (or vitamins) reported as teratogenic 
agents will be calculated as the number of unique reports divided by the number of total 
reports from participants who answered yes to the perception question and reported a 
medication or substance. 
 
Results 
 The Slone Birth Defects Study included 51,413 mothers, mean age 28.8 years, 
who were interviewed between 1976 and 2015. Excluded from this analysis were 1,855 
participants who did not provide an answer to the question concerning perception of 
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medications or other substances causing birth defects and 3,251 participants who 
answered yes to the perception question but did not identify a medication as a causative 
agent. Model 1 (Table 1) included the remaining 46,307 participants; 17,785 (38.4%) 
reported perception of one or more medications and 28,522 (61.6%) answered no to the 
perception question. Model 2 (Table 2), included 28,642 participants; 8,722 (30.4%) 
reported perception of one or more medications and 19,920 (69.6%) answered no to the 
perception question.   
 Tables 1 and 2 present the proportion of women who reported perception that 
medications may cause birth defects according to selected factors, along with crude and 
adjusted risk estimates according to model 1 and model 2 variables. In both analyses, the 
crude proportion of women who reported perception was higher for the following 
characteristics:  older maternal age, white race, higher educational levels, those who 
reported a previous pregnancy of a child with birth defects, and women who used  daily 
medications during pregnancy. After multivariable adjustment within each model, these 
variables remained significantly and independently associated but the magnitude of the 
ORs were attenuated. 
 In model 1, the crude proportion of women who reported perception was 
generally higher in those interviewed during the earlier years of the study; after 
multivariable adjustment perception remained significantly higher during the 1981 -1990 
time period compared with the following years. Both models indicate a stable rate of 
perception starting in the 1990s.   
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 The model 2 subset included the additional variables of pregnancy wantedness, 
marital status, and alcohol use. Women who wanted the pregnancy were 15% more likely 
to perceive than those who reported not wanting the pregnancy.  Women who drank 
alcohol during pregnancy were 20% more likely to perceive compared with women who 
did not drink during pregnancy. Marital status was not associated with perception. 
 Women who reported daily medication use during pregnancy were more likely to 
perceive the risk of medications in both analyses.  
 Having a baby with a birth defect in the index pregnancy, smoking status, and 
parity did not show meaningful associations. The study center variable showed minimal 
associations with the exception the Iowa center, which reported twice as many women 
who perceived compared to Boston and most other centers during the earlier years of the 
study; however, total participant size in this center was small relative to most other 
centers. 
 Testing for collinearity showed variance inflation factors less than 2 for all 
variables. 
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Table 1    Perception of the risk that medications may cause birth defects by female participants in the Slone Birth Defects 
Study, 1976 through 2015 (n=46,307) 
 
Variables Total (n) Perception of Risk (n) 
     Crude OR 
      (95% CI) 
Adjusted OR 
(95% CI) * 
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*Adjusted for all variables, n=46161 




Table 2 Perception of the risk that medications may cause birth defects by female participants in the Slone Birth Defects 
Study, 1998 through 2015 (n=28,642) 
 
Variables Total (n) Perception 
of Risk (n) 
     Crude OR 
      (95% CI) 
Adjusted OR 
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*Adjusted for all variables, n=28,432 




 Table 3 presents the 10 medications most frequently identified by the 17,785 
women who perceived teratogenic risk from medications from 1976 through 2015. These 
10 medications (and medication categories) collectively represent 39.3% of total reports 
(n=41,775). The term “all medication” was most frequently reported, followed by aspirin, 
thalidomide, oral contraceptives, Bendectin, isotretinoin, diethylstilbestrol, 
sulfamethoxazole, ibuprofen, and antidepressants.   
 
Table 3 Ten most frequently reported medications perceived as teratogenic by 17,785 
female participants in the Slone Birth Defects Study, 1976- 2015 
 
Reported Term Number (%) ** 
 
all medication 3176 (7.6) 
aspirin 2651 (6.3) 
thalidomide 1868 (4.5) 
oral contraceptives 1833 (4.4) 
Bendectin* 1488 (3.6) 
isotretinoin 1497 (3.5) 
diethylstilbestrol 1344 (3.2) 
sulfamethoxazole 1011 (2.4) 
ibuprofen   850 (2.0) 
antidepressants 741(1.8) 
 
*contains doxylamine, pyridoxine 
**total reports = 41,775 from 21,036 participants who answered yes to the perception 
question and reported a medication or substance  
 
 
Including women in the analysis who answered yes to the perception question but 
did not report a medication (or vitamin) did not change the overall associations 
(Appendix B and C). 
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 Similar secular trends and associations were observed when restricting the 
definition of perception to only those who perceived one or more of the known teratogens 
thalidomide, isotretinoin, or diethylstilbestrol and comparing them to women who did not 
perceive, who perceived other medications, and who perceived only non-medication 
substances. An exception was the association of having a previous baby with a birth 
defect and increased perception was null in the model 2 analysis (Appendix D and E). 
 
Discussion 
 Data did not support the hypothesis that the proportion of women who perceive 
medications as potentially teratogenic has increased over the past 4 decades, a prediction 
based on the increase in scientific and lay publications concerning this issue during that 
time period. This was despite a broadening of the study’s perception question to include 
“anything else” in addition to medications; this change occurred in 1988.  Rather, we 
observed an overall decrease in perception which may reflect the increase in time 
following the thalidomide disaster of the 1960s and the (misplaced) concerns about the 
teratogenicity of Bendectin in the early 1980s.  Thalidomide was stated in 13% of all 
reports during the first 5-year study period compared with only 1% during the last 5-year 
study period, and Bendectin was stated in 6 % of all reports during 1981-85 and 0 % in 
the last 5-year period (data not shown). 
 The study data support independent associations of older maternal age, white 
race, higher educational levels, and those who reported a previous pregnancy of a child 
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with birth defects with higher levels of perception concerning the risks of medications 
potentially causing birth defects during pregnancy. Some of these findings might be 
attributed to an increased awareness of this issue in older, perhaps more experienced or 
educated mothers, and in those who have had a previous poor birth outcome.  Reinforcing 
the potential role played by education among pregnant women,  an earlier Slone BDS 
study using a portion of the same population found  white race and higher educational 
levels to be independent predictors in the awareness of benefits from folic acid in 
preventing neural tube defects during pregnancy, 13. 
 Women who wanted the pregnancy perceived risk more than those who reported 
not wanting the pregnancy;  this might reflect a higher level of interest in this issue 
among those planning a pregnancy. 
 Women who reported taking one or more daily medications during pregnancy 
were more likely to perceive the risk of medications as compared with women who did 
not take a daily medication; this may represent a heightened awareness of potential risk 
among these women. 
 The lack of an increase in perception in women who had a baby with a birth 
defect (index birth) compared with women who had an unaffected  infant does not 
support the likelihood of recall bias in women who had a baby with a birth defect.  
 Of the ten most commonly perceived teratogenic medications reported in the 
1976-2015 study period (Table 3), many are not considered teratogens. This phenomenon 
has been reported in previous studies.8,9   The most commonly reported term in this study, 
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“All medications” may cause birth defects, is not correct.  Of the top ten medications 
reported; thalidomide, isotretinoin, and diethylstilbestrol are established teratogens.14 
 The strength of the study is the extensive data obtained from more than 50,000 
women over 4 decades and the inclusion of the question related to perception. The Slone 
BDS data has been utilized in hundreds of publications evaluating the exposure of 
medications and vitamins in relationship to the development of birth defects.  
 A limitation of this study is that the variables of wanted pregnancy and marital 
status were not fully added to the questionnaire until 1998, limiting analysis of their 
association with perception to the later years of the study.  Medication frequencies 
reported in table 3 are based on total reports of those who perceived one or more 
medications (17,785) and those that perceived risk but did not identify a medication 
(3,251). This does not affect the rank order of the medications listed but could 
underestimate the percent frequencies as compared to restricting the denominator to 
reports from only those participants who perceived at least one or more medications. 
 In conclusion, this study suggests a general trend over the past four decades 
towards less perception by women that medications may cause birth defects. The study 
does not support the likelihood of recall bias in women who gave birth to a baby with a 
birth defect,  an important concern in epidemiological studies of birth defects.  The study 
also supports previous findings that demonstrate a misunderstanding about what specific 
medications may cause birth defects. It has previously been shown that counseling 
pregnant woman can decrease the misperception of teratogenic risk from medications 
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used for nausea and vomiting of pregnancy15.  Other researchers have suggested that 
greater use of drug information centers, such as the Norwegian network of drug 
information centers (RELIS), might help guide pregnant women and prescribing 







1976-1983 “Are you aware of any medications that may cause birth defects in humans?” 
1983-1987 “Have you heard that there are any medications that may cause birth defects in humans?” 
1988-1992 “Have you heard there are any medications, vitamins or anything else that may cause birth defects in humans” 
1992-1998 “Have you heard there are any medications, vitamins or anything else that may cause birth defects?” 
1998-2015 “Have you heard of any medication, vitamin or anything else that may cause birth defects?” 
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Appendix B    Perception of the risk that medications may cause birth defects by female participants in the Slone Birth Defets 
Study, 1976 through 2015 (n=49558) 
 




(95% CI) * 
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18331 (43.1%) 











Appendix C  Perception of the risk that medications may cause birth defects by female participants in the Slone Birth Defects 
Study, 1998 through 2015 (n=30532) 
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Appendix D    Perception of the risk that known teratogenic medications may cause birth defects by female participants in the 
Slone Birth Defects Study, 1976 through 2015 (n=49558) 
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Appendix E  Perception of the risk that known teratogenic medications may cause birth defects by female participants in the 
Slone Birth Defects Study, 1998 through 2015 (n=30532) 
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0.87 (0.76-0.99) 
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*Adjusted for all variables, n=30307 
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